Corcept Therapeutics (CORT), Monday announced that its Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel for platinum-resistant ovarian cancer met its primary endpoint, showing a 30 percent reduction in disease progression risk.
Patients receiving the combination had a median progression-free survival of 6.5 months versus 5.5 months for chemotherapy alone. Interim results also showed a significant overall survival benefit.
Relacorilant was well-tolerated, with no new safety concerns. Full trial results will be presented later this year, and Corcept plans to submit regulatory applications in the coming months.
CORT is currently trading at $102.26, up $47.63 or 87.20 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.